<?xml version="1.0" encoding="UTF-8"?>
<p id="para0032">The nucleoside analogue remdesivir (GS-5734) was reported to inhibit SARS-CoV and MERS-CoV in vivo 
 <xref rid="bib0084" ref-type="bibr">[84</xref>,
 <xref rid="bib0085" ref-type="bibr">85]</xref>. More recently, an in vitro study showed that remdesivir potently blocked SARS-CoV-2 infection at low-micromolar concentrations and showed a high selectivity index 
 <xref rid="bib0079" ref-type="bibr">[79]</xref>. In addition, the first case of SARS-CoV-2 infection in the USA was treated with intravenous remdesivir when the patient's condition deteriorated 
 <xref rid="bib0041" ref-type="bibr">[41]</xref>. Although remdesivir has some benefits for the treatment of COVID-19 pneumonia, randomised controlled trials are still required to determine its efficacy and safety.
</p>
